NO831565L - Hoeyredreiende isomerer av derivater av 1-aza-bicyklo-(2,2,2)-oktan og fremgangsmaate for deres fremstilling - Google Patents
Hoeyredreiende isomerer av derivater av 1-aza-bicyklo-(2,2,2)-oktan og fremgangsmaate for deres fremstillingInfo
- Publication number
- NO831565L NO831565L NO831565A NO831565A NO831565L NO 831565 L NO831565 L NO 831565L NO 831565 A NO831565 A NO 831565A NO 831565 A NO831565 A NO 831565A NO 831565 L NO831565 L NO 831565L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutically acceptable
- group
- active substance
- compound
- formula
- Prior art date
Links
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical class C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 title claims description 11
- 238000000034 method Methods 0.000 title description 11
- 238000002360 preparation method Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000001430 anti-depressive effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 206010022714 Intestinal ulcer Diseases 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 4
- 230000001262 anti-secretory effect Effects 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical group CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- FJASYYACMTUWRJ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl benzenesulfonate Chemical compound C1N(CC2)CCC2C1OS(=O)(=O)C1=CC=CC=C1 FJASYYACMTUWRJ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 108010079943 Pentagastrin Proteins 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 2
- 229960000444 pentagastrin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960000279 quinupramine Drugs 0.000 description 2
- JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- XETLOFNELZCXMX-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(4-hexoxyphenyl)-2-hydroxy-2-phenylacetate;hydrochloride Chemical compound Cl.C1=CC(OCCCCCC)=CC=C1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 XETLOFNELZCXMX-UHFFFAOYSA-N 0.000 description 1
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 1
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 1
- -1 5-[1-aza bicyclo(2,2,2)oct-3(S)-yl]-10,11-dihydro-5H-dibenz(b ,f) azepine Chemical compound 0.000 description 1
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical compound C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8207703A FR2526433B1 (fr) | 1982-05-04 | 1982-05-04 | Isomeres dextrogyres de derives de l'aza-1 bicyclo (2,2,2) octane, leur procede de preparation et medicaments les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO831565L true NO831565L (no) | 1983-11-07 |
Family
ID=9273691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO831565A NO831565L (no) | 1982-05-04 | 1983-05-03 | Hoeyredreiende isomerer av derivater av 1-aza-bicyklo-(2,2,2)-oktan og fremgangsmaate for deres fremstilling |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0093643A1 (el) |
| JP (1) | JPS58203990A (el) |
| AU (1) | AU1419383A (el) |
| DK (1) | DK197583A (el) |
| ES (1) | ES522063A0 (el) |
| FR (1) | FR2526433B1 (el) |
| GR (1) | GR72287B (el) |
| IL (1) | IL68264A0 (el) |
| MA (1) | MA19786A1 (el) |
| NO (1) | NO831565L (el) |
| PT (1) | PT76487B (el) |
| ZA (1) | ZA833137B (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8615785D0 (en) * | 1986-06-27 | 1986-08-06 | Beecham Group Plc | Compounds |
| DE3789039T2 (de) * | 1986-06-27 | 1994-06-09 | Beecham Group Plc | Verbrückte bicyclische N-heterocyclische Verbindungen. |
| IT1251161B (it) * | 1991-08-07 | 1995-05-04 | Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1250534A (el) * | 1969-03-03 | 1971-10-20 | ||
| FR2052991A1 (en) * | 1969-06-20 | 1971-04-16 | Sogeras | N-(dibenzo (bf) azepines quinuclidines |
| FR2318638A2 (fr) * | 1975-07-25 | 1977-02-18 | Sogeras | Nouveaux derives de la phenothiazine et procede pour leur preparation |
-
1982
- 1982-05-04 FR FR8207703A patent/FR2526433B1/fr not_active Expired
-
1983
- 1983-03-28 IL IL68264A patent/IL68264A0/xx unknown
- 1983-03-31 PT PT76487A patent/PT76487B/pt unknown
- 1983-04-13 GR GR71071A patent/GR72287B/el unknown
- 1983-04-22 EP EP83400801A patent/EP0093643A1/fr not_active Withdrawn
- 1983-04-28 MA MA20006A patent/MA19786A1/fr unknown
- 1983-05-02 JP JP58076351A patent/JPS58203990A/ja active Pending
- 1983-05-03 ES ES522063A patent/ES522063A0/es active Granted
- 1983-05-03 AU AU14193/83A patent/AU1419383A/en not_active Abandoned
- 1983-05-03 ZA ZA833137A patent/ZA833137B/xx unknown
- 1983-05-03 NO NO831565A patent/NO831565L/no unknown
- 1983-05-03 DK DK197583A patent/DK197583A/da unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK197583D0 (da) | 1983-05-03 |
| ES8407035A1 (es) | 1984-09-01 |
| ZA833137B (en) | 1984-01-25 |
| DK197583A (da) | 1983-11-05 |
| AU1419383A (en) | 1983-11-17 |
| IL68264A0 (en) | 1983-06-15 |
| FR2526433A1 (fr) | 1983-11-10 |
| GR72287B (el) | 1983-10-17 |
| FR2526433B1 (fr) | 1985-10-18 |
| MA19786A1 (fr) | 1983-12-31 |
| PT76487A (fr) | 1983-04-01 |
| EP0093643A1 (fr) | 1983-11-09 |
| ES522063A0 (es) | 1984-09-01 |
| JPS58203990A (ja) | 1983-11-28 |
| PT76487B (fr) | 1985-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI95464B (fi) | Menetelmä terapeuttisesti käyttökelpoisen 4-(di-n-propyyli)amino-6-aminokarbonyyli-1,3,4,5-tetrahydrobentso/c,d/indolihippuraatin valmistam iseksi | |
| BR122014023207A2 (pt) | Compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos | |
| DK159441B (da) | 11-substituerede 5,11-dihydro-6h-dibenz(b,e)azepin-6-on-derivater, laegemidler indeholdende disse forbindelser og analogifremgangsmaade til forbindelsernes fremstilling | |
| US3379729A (en) | Piperazinyldibenzothiepins | |
| NO831565L (no) | Hoeyredreiende isomerer av derivater av 1-aza-bicyklo-(2,2,2)-oktan og fremgangsmaate for deres fremstilling | |
| GB2142332A (en) | Spirosuccinimide derivatives | |
| JPS6040422B2 (ja) | 置換１‐アルキルチオフエニル―２，３，４，５―テトラヒドロ―１ｈ―３―ベンズアゼピン化合物 | |
| GB2120662A (en) | New azepinoindoles, their production and pharmaceutical compositions containing them | |
| CH637653A5 (de) | In 11-stellung substituierte 5,11-dihydro-6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
| NO174053B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive r(-) 3-kinuklidinol-derivater | |
| US4668674A (en) | (+)-6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)-acetyl]-11H-dibenzo[b,][1,4]diazepin-11-one, the isolation thereof and its use as a pharmaceutical material | |
| JPH01313477A (ja) | トランス‐ヘキサヒドロ‐８‐ヒドロキシ‐２，６‐メタノ‐２ｈ‐キノリジン‐３（４ｈ）‐オンのインドール‐３‐カルボン酸エステル類の製法 | |
| EP0233049A1 (en) | 2,3,4,8,9,9a-Hexahydro-4-aryl-1H-indeno[1,7-cd]azepines | |
| CA1161857A (en) | 3-amino-1-benzoxepin derivatives, their salts and pharmaceutical compositions thereof and process for their preparation | |
| US3086972A (en) | Aza-thiaxanthene derivatives | |
| US4206210A (en) | Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity | |
| CA1090334A (en) | Alkylthio-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro- 1h-3-benzazepines having dopaminergic activity | |
| JPH03501389A (ja) | 新規チエニルオキシ‐アルキルアミン誘導体、その製法及びこの化合物を含有する医薬 | |
| IE44228B1 (en) | A 3-/2-/4(10,11-dihydro-dibenzo/b,f/thiepin-10-yl)-1-piperazinyl/-ethyl/-2-oxazolidinone and salts thereof | |
| US4031225A (en) | 4H-Benzo[4,5]cyclohepta[1,2-b]thiophenes | |
| JPS60116678A (ja) | ｎ‐プロパノールアミン誘導体エーテル | |
| EP0043729B1 (en) | New dopaminergic isoquinolines | |
| US3564015A (en) | Derivatives of dibenzocycloheptenes | |
| JPS58148883A (ja) | ピリドベンゾジアゼピノン化合物 | |
| JPS62425A (ja) | 医薬組成物 |